医薬品有力企業シリーズ: 眼薬メーカー上位25社分析2016-2026

◆英語タイトル:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026
◆商品コード:VGAIN60620
◆発行会社(調査会社):visiongain
◆発行日:2016年5月
◆ページ数:220
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Sigle User(1名利用)GBP1,999 ⇒換算¥291,854見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥437,854見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥729,854見積依頼/購入/質問フォーム
※visiongain社発行の調査レポートは、Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。

販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongain社の日本における正規販売代理店です。visiongain社の概要及び新刊レポートはこちらでご確認いただけます。
当調査レポートでは、世界の眼薬メーカー上位25社について調査・分析し、以下の構成でお届けいたします。
1. レポート概要

2. 眼薬の概要

3. 眼薬: 世界市場 2016-2026

4. 米国の主要眼薬メーカー 2016-2026

5. 欧州の主要眼薬メーカー 2016-2026

6. アジア太平洋地域およびその他地域の主要眼薬メーカー 2016-2026

7. 2016年の新興眼薬メーカー

8. 眼薬市場の定性分析 2016-2026

9. 結論

10. 用語集
【レポートの概要】

What can be expected from the ophthalmic drugs market? Which companies are going to be most successful in the next 10 years? Which therapeutic areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects in the market.

Our 220-page report provides 160 tables, charts, and graphs. Discover the most successful companies, the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole ophthalmic drugs market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

In the report also you will find revenue forecasts to 2026 for the following submarkets in the ophthalmic drugs market:
• Retinal Disorder Drugs
• Allergic, Inflammatory & Infective Drugs
• Glaucoma Drugs
• Dry Eye Drugs
• Other Ophthalmic Drugs

Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026: Companies Looking to Replicate Wet AMD Drug Successes in Dry AMD, Glaucoma and Allergic, Inflammatory & Infective Ocular Conditions

The report provides detailed profiles and revenue forecasts to 2026 for the following key companies operating within the ophthalmic drugs market:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju
• Akorn

The report also includes revenue forecasts to 2026 for the following ophthalmic drugs:
• Eylea
• Lucentis
• Restasis
• Lumigan and Ganfort
• Travatan/Travatan Z and DuoTrav
• Alphagan/Alphagan P and Combigan
• Vigamox
• Xalatan/Xalacom
• Azopt
• Jetrea
• Hyalein
• Cosopt
• Tapros/Taflotan
• Diquas
• Cravit
• Alesion
• Lotemax

Leading companies and potential for market growth
Novartis (including subsidiary Alcon) will remain the leading ophthalmic company to 2026, our work forecasts. We predict strong revenue growth across the ophthalmic drugs market through to 2026. Advances in ocular drug delivery, treatments which address areas of unmet clinical need and the launch of several new therapies across all submarkets will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain’s analysis of over 25 leading companies, including these:
• Novartis
• Regeneron
• Allergan
• Roche
• Valeant
• Santen
• Bayer
• Pfizer
• Senju
• Akorn

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Revenue forecasts to 2016 for ophthalmic drugs marketed by the company
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

What issues will affect the ophthalmic drugs industry?
Our new report discusses issues and events affecting the ophthalmic drugs market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Emerging therapies with the potential to reshape the market

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2016-2026 report helps you
In summary, our 220-page report gives you the following knowledge:
• Revenue forecasts to 2026 for the 10 leading companies in the market – discover the industry’s prospects for companies including: Novartis, Regeneron, Allergan, Roche, Valeant, Santen, Bayer, Pfizer, Senju and Akorn
• Revenue forecasts to 2026 for each major submarket – discover prospects for leading ophthalmic drugs in the following areas: retinal disorder drugs, allergic, inflammatory & infective drugs, glaucoma drugs and dry eye drugs.
• Revenue forecasts to 2026 for 17 leading drugs – discover prospects for leading ophthalmic drugs including: Eylea, Lucentis, Restasis, Lumigan and Ganfort, Travatan/Travatan Z and DuoTrav, Alphagan/Alphagan P and Combigan, Vigamox, Xalatan/Xalacom, Azopt, Jetrea, Hyalein, Cosopt, Tapros/Taflotan, Diquas, Cravit, Alesion and Lotemax.
• Assessment of 21 emerging ophthalmic companies – analysis of products, revenue, mergers & acquisitions and leading pipeline drug candidates
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain’s study is for everybody needing commercial analyses for the ophthalmic drugs market and leading companies. You will find data, trends and predictions. Please order our report now.

【レポートの目次】

1. Report Overview
1.1 Global Ophthalmic Drugs Market Overview
1.2 Global Ophthalmic Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2. Introduction to Ophthalmic Drugs
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 The Global Burden of Eye Disease
2.3 Ophthalmic Drugs: Market Segmentation
2.4 Glaucoma: the ‘Silent Thief of Sight’
2.4.1 A Classification of Glaucoma
2.4.1.1 Primary Open-Angle Glaucoma
2.4.1.2 Acute Angle-Closure Glaucoma
2.4.1.3 Congenital Glaucoma
2.4.1.4 Secondary Glaucoma
2.4.1.5 Normal-Tension Glaucoma
2.4.1.6 Ocular Hypertension
2.4.2 Risk Factors for Glaucoma
2.4.3 Diagnosis of Glaucoma
2.4.4 Drug Treatment of Glaucoma
2.4.5 Laser Treatment and Surgery for Glaucoma
2.5 Age-Related Macular Degeneration (AMD)
2.5.1 Dry (non-exudative) AMD
2.5.2 Wet (exudative) AMD
2.5.3 Risk Factors for AMD
2.5.4 Diagnosis of AMD
2.5.5 Treatment of AMD
2.6 Diabetic Retinopathy (DR)
2.6.1 Diagnosis of Diabetic Retinopathy
2.6.2 Treatment of Diabetic Retinopathy
2.7 Ocular Allergy and Allergic Conjunctivitis
2.7.1 Diagnosis of Ocular Allergy
2.7.2 Treatment of Ocular Allergy
2.8 Ocular Inflammatory Disease
2.8.1 Treatment of Ocular Inflammatory Disease
2.9 Eye Infections
2.9.1 Treatment of Eye Infections
2.10 Dry Eye Syndrome
2.10.1 Treatment of Dry Eye Syndrome
2.11 Phases of Clinical Trials
2.12 Currency Exchange Rates in This Report

3. Ophthalmic Drugs: World Market 2016-2026
3.1 The World Ophthalmic Drugs Market in 2015
3.2 World Ophthalmic Drugs Market: Sales Forecast 2016-2026
3.3 Leading Ophthalmic Drugs
3.4 Leading Companies in the Ophthalmic Drugs Market
3.4.1 Top 25 Ophthalmic Drug Manufacturers
3.5 Ophthalmic Drugs Market Segments: Sales Forecasts 2016-2026
3.5.1 Retinal Disorders Drugs Market: Sales Forecast 2016-2026
3.5.2 Allergic, Inflammatory and Infective Drugs Market: Sales Forecast 2016-2026
3.5.3 Glaucoma Drugs Market: Sales Forecast 2016-2026
3.5.4 Dry Eye Drugs Market: Sales Forecast 2016-2026
3.5.5 Other Ophthalmic Drugs Market: Sales Forecast 2016-2026
3.6 How Will Market Shares Change to 2026?
3.7 World Ophthalmic Drugs Market: Drivers and Restraints 2016-2026
3.7.1 World Ophthalmic Drugs Market: Analysis of Drivers
3.7.2 World Ophthalmic Drugs Market: Analysis of Restraints

4. Leading US Ophthalmic Drug Manufacturers 2016-2026
4.1 Allergan Overview
4.1.1 Allergan: Ophthalmic Product Portfolio
4.1.1.1 Restasis: Generic Launch in 2016?
4.1.1.2 Restasis: Sales Forecast 2016-2026
4.1.1.3 Lumigan and Ganfort: Marketed in Over 67 Countries
4.1.1.4 Lumigan and Ganfort: Sales Forecast 2016-2026
4.1.1.5 Refresh Brand Products: the Range
4.1.1.6 Alphagan/Alphagan P and Combigan: Extended Lifecycle
4.1.1.7 Alphagan/Alphagan P and Combigan: Sales Forecast 2016-2026
4.1.1.8 Acular: New Forms Receiving FDA Approvals
4.1.1.9 Ozurdex (Dexamethasone Intravitreal Implant): The First Drug Therapy for Diabetic Macular Edema
4.1.2 Allergan: Late Stage Ophthalmic Product Pipeline
4.1.3 Allergan: Ophthalmic Revenue Forecast 2016-2026
4.1.3.1 Allergan: Ophthalmic Drugs Market Share Forecast 2016-2026
4.1.4 Allergan: SWOT Analysis
4.2 Pfizer Overview
4.2.1 Pfizer: Ophthalmic Product Portfolio
4.2.1.1 Xalatan/Xalacom: First Ophthalmic Blockbuster
4.2.1.2 Xalatan/Xalacom: Sales Forecast 2016-2026
4.2.2 Pfizer: Ophthalmic Product Pipeline
4.2.3 Pfizer: Revenue Forecast 2016-2026
4.2.3.1 Pfizer: Ophthalmic Drugs Market Share Forecast 2016-2026
4.2.4 Pfizer: SWOT Analysis
4.3 Regeneron Overview
4.3.1 Regeneron: Ophthalmic Product Portfolio
4.3.1.1 Eylea: Superior Clinical Outcomes than Lucentis and Avastin?
4.3.1.2 Eylea: US Sales Forecast 2016-2026
4.3.2 Regeneron: Ophthalmic Product Pipeline
4.3.3 Regeneron: Revenue Forecast 2016-2026
4.3.3.1 Regeneron: Ophthalmic Drugs Market Share Forecast 2016-2026
4.3.4 FDA Approves Zaltrap (aflibercept)
4.3.5 Eylea/Zaltrap and the Davis-Smyth Patent Agreements
4.3.6 Regeneron: SWOT Analysis
4.4 Akorn Overview
4.4.1 Akorn: Ophthalmic Product Portfolio
4.4.1.1 AzaSite: AzaSite Plus and AzaSite Xtra Set to Drive AzaSite Sales
4.4.1.2 Cosopt/Cosopt PF: Acquired from Merck
4.4.2 Akorn: Revenue Forecast 2016-2026
4.4.2.1 Akorn: Ophthalmic Drugs Market Share Forecast 2016-2026
4.4.3 Akorn: SWOT Analysis

5. Leading European Ophthalmic Drug Manufacturers 2016-2026
5.1 Bayer Overview
5.1.1 Bayer: Ophthalmic Product Pipeline
5.1.2 Eylea: non-US Sales Forecast 2016-2026
5.1.3 Bayer: Revenue Forecast 2016-2026
5.1.3.1 Bayer: Ophthalmic Drugs Market Share Forecast 2016-2026
5.2 Novartis (including Alcon) Overview
5.2.1 Novartis: Ophthalmic Product Portfolio
5.2.1.1 Lucentis: Still a Leading Drug in AMD
5.2.1.2 Lucentis: Non-US Sales Forecast 2016-2026
5.2.1.3 Travatan/Travatan Z and DuoTrav: DuoTrav Awaiting US Approval
5.2.1.4 Travatan/Travatan Z and DuoTrav: Sales Forecast 2016-2026
5.2.1.5 Vigamox: Competes with Alcon’s Moxeza
5.2.1.6 Vigamox: Sales Forecast 2016-2026
5.2.1.7 Azopt: Marketed in Major Markets
5.2.1.8 Azopt: Sales Forecast 2016-2026
5.2.1.9 Jetrea: Sales Revenues Fall Short
5.2.1.10 Jetrea: Non-US Sales Forecast 2016-2026
5.2.2 Novartis: Ophthalmic Product Pipeline
5.2.2.1 Finafloxacin (MerLion Pharmaceuticals/Novartis)
5.2.2.2 AKB 9778 (Aerpio Therapeutics)
5.2.3 Novartis: Revenue Forecast 2016-2026
5.2.3.1 Novartis: Ophthalmic Drugs Market Share Forecast 2016-2026
5.2.4 Novartis: SWOT Analysis
5.3 Roche Overview
5.3.1 Roche: Ophthalmic Product Portfolio
5.3.1.1 Lucentis: US Sales Forecast 2016-2026
5.3.1.2 Avastin: Off-Label Use for Wet AMD Cannibalising Lucentis Sales
5.3.1.3 Avastin: Sales Forecast 2016-2026
5.3.2 Roche: Ophthalmic Product Pipeline
5.3.2.1 Lampalizumab (RG7417)
5.3.3 Roche: Revenue Forecast 2016-2026
5.3.3.1 Roche: Ophthalmic Drugs Market Share Forecast 2016-2026
5.3.4 Roche: SWOT Analysis

6. Leading Asia-Pacific and Other Ophthalmic Drug Manufacturers 2016-2026
6.1 Santen Overview
6.1.1 Santen: Ophthalmic Product Portfolio
6.1.1.1 Eylea: Japan Sales Forecast 2016-2026
6.1.1.2 Hyalein
6.1.1.3 Hyalein: Sales Forecast 2016-2026
6.1.1.4 Cosopt: Non-US Sales Forecast 2016-2026
6.1.1.5 Tapros/Taflotan: Sales Forecast 2016-2026
6.1.1.6 Diquas: Sales Forecast 2016-2026
6.1.1.7 Cravit: Higher Concentration Showing Significant Efficacy
6.1.1.8 Cravit: Sales Forecast 2016-2026
6.1.1.9 Alesion: Sales Forecast 2016-2026
6.1.2 Santen: Ophthalmic Product Pipeline
6.1.3 Santen: Revenue Forecast 2016-2026
6.1.3.1 Santen: Ophthalmic Drugs Market Share Forecast 2016-2026
6.1.4 Santen: SWOT Analysis
6.2 Senju Overview
6.2.1 Senju: Ophthalmic Product Portfolio
6.2.2 Senju: Ophthalmic Product Pipeline
6.2.2.1 Y 39983 (SNJ 1656)
6.2.2.2 Difluprednate (SJE-2079)
6.2.3 Senju: Revenue Forecast 2016-2026
6.2.3.1 Senju: Ophthalmic Drugs Market Share Forecast 2016-2026
6.2.4 Senju: SWOT Analysis
6.3 Valeant Overview
6.3.1 Valeant: Ophthalmic Product Portfolio
6.3.1.1 Lotemax: New Formulation Launch Expected in 2016
6.3.1.2 Lotemax: Sales Forecast 2016-2026
6.3.2 Valeant: Ophthalmic Product Pipeline
6.3.2.1 Vesneo (Latanoprostene Bunod)
6.3.2.2 Brimonidine tartarate 0.0025% for Eye Whitening (Valeant)
6.3.3 Valeant: Revenue Forecast 2016-2026
6.3.3.1 Valeant: Ophthalmic Drugs Market Share Forecast 2016-2026
6.3.4 Valeant: SWOT Analysis
6.3.4.1 Valeant’s Acquisition of Bausch and Lomb: Aggressive Expansion?
6.3.4.2 Valeant: Difficult End to 2015 Puts Company Future in Doubt

7. Emerging Ophthalmic Drug Manufacturers in 2016
7.1 Companies with Small Ophthalmic Portfolios and Promising Pipeline Candidates, 2016
7.2 Acucela
7.3 Aerie Pharmaceuticals
7.4 Aerpio Therapeutics: Developing AKB 9778
7.5 Alimera Sciences
7.5.1 Iluvien: Increasing Geographical Reach and Increasing Sales
7.5.2 NADPH Oxidase Inhibitors Offer Potential for Dry AMD
7.6 Amakem
7.7 Ampio Pharmaceuticals
7.8 Chengdu Kanghong Pharmaceutical
7.9 Eleven Biotherapeutics
7.10 EyeGate Pharmaceuticals
7.11 Gene Signal
7.11.1 Aganirsen: Preventing Corneal Graft Rejection
7.12 Icon Bioscience
7.13 MacuCLEAR
7.13.1 MC 1101: a Potential Therapy for Dry AMD
7.14 Neurotech
7.15 Omeros
7.16 OphthaliX (Can-Fite BioPharma)
7.17 Ophthotech
7.17.1 Fovista: Potential Game-Changer in AMD
7.17.2 Fovista: Significant Improvement on Lucentis in Phase II Trials
7.17.3 Zimura: Complement C5 Inhibitor
7.18 Otsuka Pharmaceutical
7.19 pSivida Corp.
7.20 RXi Pharmaceuticals: Will Bevasiranib Resume Development?
7.21 Shire
7.21.1 Lifitegrast (SHP606) for Dry Eye
7.21.2 Premiplex (SHP607): Preventing Retinopathy of Prematurity
7.22 ThromboGenics
7.22.1 Jetrea (ocriplasmin)
7.22.2 ThromboGgenics: Leading Diabetic Eye Disease Pipeline

8. Qualitative Analysis of the Ophthalmic Drugs Market 2016-2026
8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market
8.1.1 Rivalry Among Competitors [Medium] 8.1.2 Threat of New Entrants [Low] 8.1.3 Power of Suppliers [Low] 8.1.4 Power of Buyers [Medium] 8.1.5 Threat of Substitutes [Medium]

9. Conclusions
9.1 Ophthalmic Pharmaceuticals: A Growing Niche Market
9.2 The World Ophthalmic Drugs Market in 2015
9.2.1 Leading Ophthalmic Drugs Market Segments
9.2.2 Leading Ophthalmic Drugs
9.2.3 Leading Ophthalmic Drugs Companies
9.3 World Ophthalmic Drugs Market Forecast 2016-2026
9.4 The Future of the Ophthalmic Drugs Market?
9.4.1 Increasing Revenue Concentration among Specialist Companies
9.4.2 The Rise of Generics
9.4.3 Small Companies Can Have a Big Impact
9.4.4 What Will Succeed in the Ophthalmic Drugs Market?

10. Glossary

Table 2.1 ICD‑10 Classification of Visual Impairment, 2010
Table 2.2 Drug Treatments for Glaucoma, 2016
Table 2.3 Drug Treatments for AMD, 2016
Table 2.4 Drug Treatments for Ocular Allergy, 2016
Table 2.5 Drug Treatments for Ocular Inflammatory Disease, 2016
Table 2.6 Selected Drug Treatments for Eye Infections, 2016
Table 2.7 Clinical Trial Phases
Table 2.8 Currency Exchange Rates, 2015
Table 3.1 World Ophthalmic Drugs Market: Revenue ($m) and Market Share (%) by Segment, 2015
Table 3.2 World Ophthalmic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2015-2026
Table 3.3 Top 10 Ophthalmic Drugs: Revenue ($m), Market Share (%), Rank, Active Ingredient and Manufacturer, 2015
Table 3.4 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Market Share (%), 2015
Table 3.5 Top 25 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenue ($m), Leading Pipeline Products, 2015
Table 3.6 World Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Segment, 2015-2026
Table 3.7 Retinal Disorders Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2026
Table 3.8 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.9 Glaucoma Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.10 Dry Eye Drugs Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2015-2026
Table 3.11 Other Ophthalmic Drugs Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2015-2026
Table 3.12 Market Shares (%) of the Ophthalmic Drugs Market by Segment, 2015, 2020 and 2026
Table 4.1 Allergan: Overview, 2016
Table 4.2 Allergan: Ophthalmic Drug Products, Revenue ($m), Growth Rate (%), 2014 and 2015
Table 4.3 Allergan: Restasis Revenue ($m), AGR (%) and CAGR (%), 2015-2026
Table 4.4 Allergan: Lumigan and Ganfort Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.5 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.6 Allergan: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.7 Allergan: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 4.8 Allergan: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 4.9 Pfizer: Overview, 2016
Table 4.10 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.11 Pfizer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.12 Pfizer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 4.13 Pfizer: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 4.14 Regeneron: Overview, 2016
Table 4.15 Regeneron: Eylea Revenue ($m), AGR (%) and CAGR(%) 2015-2026
Table 4.16 Regeneron: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.17 Regeneron: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 4.18 Regeneron: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 4.19 Akorn: Overview, 2016
Table 4.20 Akorn: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 4.21 Akorn: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 4.22 Akorn: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 5.1 Bayer: Overview, 2016
Table 5.2 Bayer: Eylea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.3 Bayer: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.4 Bayer: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 5.5 Novartis: Overview, 2016
Table 5.6 Novartis: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.7 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.8 Novartis: Vigamox Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.9 Novartis: Azopt Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.10 Novartis: Jetrea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.11 Novartis: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.12 Novartis: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 5.13 Novartis: Ophthalmic Drugs Market SWOT Analysis, 2015-2025
Table 5.14 Roche: Overview, 2016
Table 5.15 Roche: Lucentis Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.16 Roche: Avastin Ophthalmic Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.17 Roche: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 5.18 Roche: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 5.19 Roche: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 6.1 Santen: Overview, 2016
Table 6.2 Santen: Revenue ($m) and Revenue Share (%) by Segment, FY 2015
Table 6.3 Santen: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Date, Region, 2016
Table 6.4 Santen: Major Prescription Ophthalmic Drugs, Revenue ($m), Revenue Share (%), FY 2015
Table 6.5 Santen: Eylea Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.6 Santen: Hyalein Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.7 Santen: Cosopt Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.8 Santen: Tapros/Taflotan Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.9 Santen: Diquas Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.10 Santen: Cravit Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.11 Santen: Alesion Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.12 Santen: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.13 Santen: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 6.14 Santen: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 6.15 Senju: Overview, 2016
Table 6.16 Senju: Major Prescription Ophthalmic Drugs by Therapeutic Area, Launch Year, 2015
Table 6.17 Senju: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.18 Senju: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 6.19 Senju: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 6.20 Valeant: Overview, 2016
Table 6.21 Valeant: Lotemax Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.22 Valeant: Ophthalmic Drugs Revenue ($m), AGR (%) and CAGR(%), 2015-2026
Table 6.23 Valeant: Ophthalmic Drugs Market Share (%), Revenue ($m), 2015-2026
Table 6.24 Valeant: Ophthalmic Drugs Market SWOT Analysis, 2016-2026
Table 7.1 Otsuka Pharmaceutical: Overview of Ophthalmic Drug Pipelines, Drug Type, Indication, Country, 2015
Table 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2015, 2020 and 2026

Figure 1.1 Global Causes of Visual Impairment (% of cases), 2012
Figure 1.2 World 65+ Population Forecast: Size (millions), CAGR (%), by National Market, 2015-2026
Figure 1.3 Global Ophthalmic Drugs Market Segmentation Overview, 2016
Figure 2.1 Estimated Global Prevalence of Visual Impairment (millions of people), 2010
Figure 2.2 Estimated Global Prevalence of Visual Impairment (millions of people), 2013
Figure 2.3 Global Causes of Visual Impairment (% of cases), 2013
Figure 2.4 Classification of Glaucoma, 2016
Figure 2.5 Global Causes of Blindness (% of cases), 2013
Figure 3.1 World Ophthalmic Drugs Market: Revenues ($m) by Segment, 2015
Figure 3.2 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2015
Figure 3.3 World Ophthalmic Drugs Market Forecast: Revenue ($m) and AGR(%), 2015-2026
Figure 3.4 Top 10 Ophthalmic Drugs: Market Share (%), 2015
Figure 3.5 Top 10 Ophthalmic Drugs: Revenues ($m), 2015
Figure 3.6 Top 10 Ophthalmic Drug Manufacturers: Ophthalmic Drugs Revenues ($m), 2015
Figure 3.7 Top 10 Ophthalmic Drug Manufacturers: Market Share (%), 2015
Figure 3.8 Retinal Disorders Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 3.9 Allergic, Inflammatory and Infective Drugs Market Forecast: Revenue ($m), 2015-2026
Figure 3.10 Glaucoma Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 3.11 Dry Eye Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 3.12 Other Ophthalmic Drugs Market Forecast: Revenues ($m), 2015-2026
Figure 3.13 World Ophthalmic Drugs Market: Market Share (%) by Segment, 2015
Figure 3.14 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2020
Figure 3.15 World Ophthalmic Drugs Market Forecast: Market Shares (%) by Segment, 2026
Figure 3.16 World Ophthalmic Drugs Market: Drivers and Restraints, 2016-2026
Figure 4.1 Allergan: Restasis Revenue ($m) and AGR (%), 2015-2026
Figure 4.2 Allergan: Lumigan and Ganfort Revenue ($m) and AGR (%), 2015-2026
Figure 4.3 Allergan: Alphagan/Alphagan P and Combigan Revenue ($m) and AGR (%), 2015-2026
Figure 4.4 Allergan: Ophthalmic Drugs Revenue ($m) and AGR (%), 2015-2026
Figure 4.5 Allergan: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 4.6 Pfizer: Xalatan/Xalacom Revenue ($m), AGR (%), 2015-2026
Figure 4.7 Pfizer: Ophthalmic Drugs Revenue ($m) and AGR (%), 2015-2026
Figure 4.8 Pfizer: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 4.9 Regeneron: Eylea Revenue ($m) and AGR(%), 2015-2026
Figure 4.10 Regeneron: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 4.11 Regeneron: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 4.12 Akorn: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 4.13 Akorn: Ophthalmic Drugs Market Share (%), 2015-2026
Figure 5.1 Bayer: Eylea Revenue ($m) and AGR(%), 2015-2026
Figure 5.2 Bayer: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 5.3 Bayer: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 5.4 Novartis: Lucentis Revenue ($m) and AGR(%), 2015-2026
Figure 5.5 Novartis: Travatan/Travatan Z and DuoTrav Revenue ($m) and AGR(%), 2015-2026
Figure 5.6 Novartis: Vigamox Revenue ($m) and AGR(%), 2015-2026
Figure 5.7 Novartis: Azopt Revenue ($m) and AGR(%), 2015-2026
Figure 5.8 Novartis: Jetrea Revenue ($m) and AGR(%), 2014-2025
Figure 5.9 Novartis: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 5.10 Novartis: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 5.11 Roche: Lucentis Revenue ($m) and AGR(%), 2015-2026
Figure 5.12 Roche: Avastin Ophthalmic Revenue ($m) and AGR(%), 2015-2026
Figure 5.13 Roche: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 5.14 Roche: Ophthalmic Drugs Revenue and Market Share (%), 2015-2026
Figure 6.1 Santen: Ophthalmic Drugs Revenue ($m) by Segment, FY 2015
Figure 6.2 Santen: Major Prescription Ophthalmic Drugs, Revenue Share (%), FY 2015
Figure 6.3 Santen: Eylea Revenue ($m) and AGR(%), 2015-2026
Figure 6.4 Santen: Hyalein Revenue ($m) and AGR(%), 2015-2026
Figure 6.5 Santen: Cosopt Revenue ($m) and AGR(%), 2015-2026
Figure 6.6 Santen: Tapros/Taflotan Revenue ($m) and AGR(%), 2015-2026
Figure 6.7 Santen: Diquas Revenue ($m) and AGR(%), 2015-2026
Figure 6.8 Santen: Cravit Revenue ($m) and AGR(%), 2015-2026
Figure 6.9 Santen: Alesion Revenue ($m) and AGR(%), 2015-2026
Figure 6.10 Santen: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 6.11 Santen: Ophthalmic Drugs Market Share (%), 2015-2026
Figure 6.12 Senju: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 6.13 Senju: Ophthalmic Drugs Market Share (%), 2015-2026
Figure 6.14 Valeant: Lotemax Revenue ($m) and AGR (%), 2015-2026
Figure 6.15 Valeant: Ophthalmic Drugs Revenue ($m) and AGR(%), 2015-2026
Figure 6.16 Valeant: Ophthalmic Drugs Market Share (%), 2015-2026
Figure 7.1 Gene Signal: Ophthalmic Drug Pipeline Progress, 2016
Figure 7.2 Ophthotech: Ophthalmic Drug Pipeline Progress, 2015
Figure 7.3 Otsuka Pharmaceutical: Ophthalmic Drug Pipeline Progress, 2016
Figure 7.4 Shire: Ophthalmic Drug Pipeline Progress, 2016
Figure 8.1 Porter’s Five Forces Analysis of the Ophthalmic Drugs Market, 2016-2026
Figure 9.1 Leading Ophthalmic Drugs Manufacturers: Revenues ($m), 2015, 2020 and 2026

★調査レポート[医薬品有力企業シリーズ: 眼薬メーカー上位25社分析2016-2026]販売に関する免責事項
★調査レポート[医薬品有力企業シリーズ: 眼薬メーカー上位25社分析2016-2026]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆